BCR – Chronic Myelogenous Leukemia, BCR-ABL1 Positive

The hallmark of chronic myelogenous leukemia (CML), BCR-ABL1-positive, is the somatic t(9;22)(q34;q11.2) translocation that fuses the 5′ portion of the breakpoint cluster region (BCR, HGNC:1014) gene on chromosome 22 to the 3′ portion of the Abelson tyrosine kinase (ABL1) gene on chromosome 9. This BCR-ABL1 fusion generates a constitutively active tyrosine kinase that drives unchecked myeloid proliferation and underlies the chronic phase of CML ([PMID:10049047]).

Genetic evidence is definitive: over 95% of CML patients harbor the canonical BCR-ABL1 fusion, with variant “simple” and “complex” translocations reported in 5–10% of cases. Four distinct variant breakpoints involving chromosomes such as 1, 5, 8, 11, 12, 15, 17, and 21 have been cytogenetically and molecularly characterized in cohorts of 72 and 420 patients, confirming that band 9q34 is always involved even when the chromosome appears cytogenetically normal ([PMID:2257543]; [PMID:8504399]). Fusion transcript types predominantly include e13a2 (b2a2) and e14a2 (b3a2), with rarer events such as e13a3 and e14a3 observed in case series.

The variant spectrum encompasses multiple in-frame fusion transcripts and breakpoint cluster regions within BCR’s major breakpoint cluster region (M-BCR). Clinical series describe e19a2 (p230), e13a3, and BCR-PDGFRA rearrangements, each correlating with distinct clinical courses and therapeutic responses. Recurrent founder transcripts manifest with thrombocytosis or leukocytosis phenotypes and inform risk stratification and monitoring.

Functional studies establish the oncogenic mechanism: BCR-ABL1’s deregulated tyrosine kinase activity transforms Ba/F3 and primary human CD34⁺ cells, and mouse xenograft models recapitulate myeloproliferation and blast crisis ([PMID:8021274]; [PMID:20554971]). BCR’s native serine/threonine kinase is inhibited upon tyrosine phosphorylation by BCR-ABL1, disrupting normal GAP activity and reinforcing leukemic signaling.

Therapeutic targeting with tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib exploits the dependence of CML cells on BCR-ABL1. Resistance arises in ~30% of patients, often due to ABL1 kinase domain mutations (e.g., p.Tyr253Phe, p.Val280Gly) or amplification of the fusion gene. RNA interference and next-generation sequencing approaches further define resistance mechanisms and support combination strategies ([PMID:25319658]; [PMID:28469513]).

Integration of genetic and experimental data confirms a definitive gene–disease association. The presence of BCR-ABL1 fusion transcripts is diagnostic, prognostic, and guides TKI-based treatment, underscoring clinical utility in CML management.

Key Take-home: BCR-ABL1 fusion detection is essential for diagnosis and targeted therapy of CML, with comprehensive fusion-typing informing prognosis and therapeutic resistance monitoring.

References

• Cancer letters • 1990 • Variant Philadelphia translocations in chronic myeloid leukemia: correlation with cancer breakpoints, fragile sites and oncogenes. PMID:2257543
• Cancer genetics and cytogenetics • 1993 • Molecular analysis of six variant Philadelphia chromosome translocations in chronic myeloid leukemia. PMID:8504399
• The Journal of biological chemistry • 1994 • Breakpoint cluster region gene product-related domain of n-chimaerin. Discrimination between Rac-binding and GTPase-activating residues by mutational analysis. PMID:8021274
• Blood • 2010 • Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. PMID:20554971
• Methods in molecular biology • 2015 • Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions. PMID:25319658
• Clinical Medicine Insights. Oncology • 2017 • BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report. PMID:28469513

Evidence Based Scoring (AI generated)